Stony Brook Cancer Center Enrolls Patients in Phase 3 Breast Cancer Vaccine Trial Targeting HER2-Positive Disease
核心洞察
Stony Brook University Hospital (搜索) is the only Long Island site participating in the worldwide FLAMINGO-01 phase 3 clinical trial testing a breast cancer vaccine for HER2 (搜索)-positive patients.
The vaccine from Greenwich LifeSciences has demonstrated an 80% or greater reduction in metastatic breast cancer (搜索) recurrence over 5 years, compared to no more than 50% reduction from other approved products.
The treatment works by injecting patients with a piece of the HER2 protein (搜索) combined with an immune adjuvant to stimulate the patient's immune system to fight cancer.
Stony Brook University Hospital (搜索) has become the sole Long Island site participating in a pivotal phase 3 clinical trial testing a promising breast cancer vaccine that could revolutionize treatment for patients with HER2 (搜索)-positive disease. The worldwide FLAMINGO-01 trial is evaluating a vaccine developed by Greenwich LifeSciences that has shown remarkable efficacy in preventing cancer recurrence.
Trial Design and Patient Population
The phase 3 trial specifically targets patients with HER2-positive breast cancer (搜索), an aggressive form of the disease that affects a significant portion of breast cancer (搜索) patients. Christina Amitrano, a 41-year-old participant who was diagnosed with stage 2 triple-positive breast cancer (搜索) at age 35, exemplifies the patient population being studied.
"It's a very aggressive type of cancer, and the HER2 (搜索)-positive aspect of it, makes it more aggressive," Amitrano explained. She is currently in her third phase of treatment to prevent cancer recurrence, having battled the disease for six years.
Mechanism of Action and Treatment Approach
The vaccine employs an innovative immunotherapeutic approach designed to harness the patient's natural immune response against cancer cells. Dr. Jules Cohen at Stony Brook Cancer Center (搜索) described the mechanism: "So patients are injected with essentially a little piece of the HER2 protein (搜索) with what's called an immune adjuvant, to sort of stimulate the immune system."
This approach represents a departure from traditional chemotherapy and radiation treatments, instead focusing on training the immune system to recognize and attack cancer cells that express the HER2 protein (搜索).
Efficacy Data and Clinical Outcomes
According to Greenwich LifeSciences, the trial has demonstrated impressive preliminary results. The company reports an 80% or greater reduction in metastatic breast cancer (搜索) recurrence over 5 years of follow-up, significantly outperforming existing treatments. This compares favorably to a reduction rate of no more than 50% from other approved products, with no serious side effects reported.
Dr. Cohen illustrated the potential clinical impact: "Say, you know, 25 out of every 100 women recur for a given type of breast cancer (搜索). And, we reduce that from 25 to say 10 percent that means we've saved 15 lives for every hundred people that we treat."
Regulatory Pathway and Future Implications
The trial represents a critical step toward potential regulatory approval and clinical implementation. As Amitrano noted, "If it's successful, then it will become the standard of care." The phase 3 designation indicates that the vaccine has already demonstrated safety and preliminary efficacy in earlier-phase studies.
The double-blind, placebo-controlled design ensures robust data collection, with participants like Amitrano not knowing whether they received the active vaccine or placebo until the trial concludes.
Broader Context of Breast Cancer Vaccine Development
The FLAMINGO-01 trial is part of a broader wave of clinical research into breast cancer (搜索) vaccines. As noted in the source materials, "There are many different clinical trials going on right now for breast cancer vaccines," indicating significant industry and academic interest in this therapeutic approach.
For patients interested in participating in the trial, Stony Brook Medicine Clinical Trials Office can be contacted at (631) 728-7425 or CancerClinicalTrials@stonybrookmedicine.edu.